trs005
zhejiang teruisi biopharmaceuticals
['trs005']
congress | #esmo22 | yuan-kai shi at the chinese academy of medical sciences presents data from a phase i trial of trs005 in pts with r/r b-cell #nhl. n=48; trs005 showed a favorable efficacy (orr:42.2%, dcr:75.6%, mpfs:4 months) and a manageable safety profile. #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm